[ad_1]
The title of BB Biotech (WKN: A0NFN3 / ISIN: CH0038389992) is an excellent alternative to special funds in the biotechnology sector. As an investment company, BB Biotech has the advantages of a capital investment. The portfolio can be proud.
The second quarter brought a return of -0.4% in CHF; 1.2% in euros and -3.9% in US dollars. The net asset value decreased by 2.8% in CHF; 1.1% in euros and 6.2% in dollars. The second quarter net loss amounted to CHF 98 million, compared to a net profit of CHF 103 million in the same period last year.
Given the challenges facing the biotech markets, the holdings were reanalyzed and corrected quickly. BB Biotech continues its strong commitment to the most innovative companies developing advanced technologies.
First, the positions on the RNA platforms were increased by buying back shares of Alnylam, previously sold at higher prices. In addition, participation in Wave Life Sciences has been increased. RNA-based therapies will continue to play an important role for a long time.
Secondly, BB Biotech extended its commitment to the specialist in gene therapy Voyager, as the company progresses well and the FDA supports such ambitious innovations. .
Source link
